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We were very interested to read the article by
Calbo et al. [1] concerning the impact of heptava-
lent pneumococcal conjugate vaccine (HPCV) on
invasive pneumococcal disease (IPD) in children
aged £5 years in a health district of Barcelona. This
kind of information is welcome and may be
helpful in clarifying the current controversy
regarding the potential limitations of HPCV in
Spain [2]. The authors found that the overall
incidence of IPD did not decline signiﬁcantly
following the introduction of HPCV in that area;
indeed, there was a 49% increase in the proportion
of cases caused by non-vaccine serotypes (p 0.01).
A trend of increasing empyemawas also apparent.
The authors acknowledged that further studies are
needed to conﬁrm these trends and to determine
the potential limitations of HPCV in Spain.
Our group has found similar results in two
ongoing studies evaluating the molecular epi-
demiology of IPD and empyema, respectively, in
children aged <14 years who were admitted to
the two largest tertiary-care hospitals in southern
Spain (5th International Symposium on Pneumo-
cocci and Pneumococcal Diseases, abstract
PO3.38) [3]. The results of these studies can be
summarised as follows:
(i) As observed by Calbo et al. [1], we saw a
relatively low vaccine uptake, even in a later
period (HPCV coverage was 29% among 515
children aged <5 years in a nasopharyngeal
colonisation study conducted during 2005).
(ii) We compared IPD cases in two time periods
(2002–2003 vs. 2004–2005), under the assump-
tion that vaccine uptake (and therefore
impact) would increase from one time period
to the next, but failed to detect an obvious
change in IPD cases (56 cases in 2002–2003 vs.
54 cases in 2004–2005). This could not be
explained by a signiﬁcant change in the
number of children in the surveillance pop-
ulation. Meningitis was diagnosed in 15
patients during each time period.
(iii) There was a signiﬁcant increase in the pro-
portion of IPD disease caused by non-vaccine
serotypes, from 33% in 2002–2003 to 62% in
2004–2005 (p <0.01), and 26% of all invasive
pneumococci belonged to serotype 1.
(iv) There was a signiﬁcant increase in the mean
number of cases of empyema between 1998–
2001 and 2002–2005 (mean 15, range 5–22, vs.
mean 43, range 27–62; p <0.02), and this
trend continued during the ﬁrst half of 2006
(46 cases). Serotype 1 was the predominant
serotype, accounting for 51% (28 ⁄ 55) of
isolates or nucleic acid extracts from pleural
ﬂuid samples since 2002. Only 16% (9 ⁄ 55) of
empyema cases were caused by vaccine
serotypes, all of which were associated with
serotype 14. Cases of empyema occurred
in relatively older children (mean age
60 months, range 10–142 months), who
therefore may be less likely to have been
immunised with HPCV.
(v) The results indicated that the contribution of
empyema to IPD is markedly underestimated
unless molecular techniques are used. Pneu-
mococcal strains were isolated by culture in
25 (25%) of 100 empyema cases diagnosed
between January 2005 and June 2006.
Evidence of pneumococcal infection was
revealed by PCR in 89% (49 ⁄ 55) of culture-
negative pleural ﬂuids available for molecu-
lar testing during this period.
(vi) Finally, based on molecular analyses, capsu-
lar switching or the arrival of new clones can
explain neither the increase in the proportion
of non-vaccine serotype-associated disease,
nor the increase in cases of empyema. Three
globally distributed clones were detected,
mainly ST228 and ST306, among serotype 1
isolates. These genotypes are well-estab-
lished clones, associated historically with
serotype 1 disease in Spain and throughout
Europe [4].
Several issues should be considered when
trying to link changes in serotype distribution—or
lack of changes in IPD levels—to vaccination.
First, the introduction of HPCV has occurred
gradually, with a very low initial vaccine uptake,
and vaccination coverage remains limited. It
might be premature to expect the incidence of
IPD among children aged <14 years—or perhaps
even <5 years—to change, since only infants and
younger children are immunised, and even then,
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only partially. Second, as indicated previously [5],
the effect of the vaccine does not readily explain
the increased incidence of childhood empyema.
This complication has increased signiﬁcantly over
the last decade, even before the introduction of
HPCV in the UK and in areas of the USA, and has
been attributed mainly to Streptococcus pneumoniae
serotype 1 [6,7]. Finally, dramatic temporal chan-
ges in the epidemiology of IPD may occur follow-
ing the spread of clones of serotype 1. These clones
have caused outbreaks of IPD at the local, commu-
nity and nationwide levels, and have been gener-
ally associated with pulmonary disease and, to a
lesser extent, with meningitis [8,9].
In conclusion, more comprehensive surveil-
lance of a highly immunised population at the
national level, supported by molecular epidemi-
ological analyses, is needed before ﬁrm conclu-
sions regarding the impact of HPCV on IPD in
Spain can be reached.
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Identiﬁcation of a novel blaOXA-51 variant,
blaOXA-92, from a clinical isolate of
Acinetobacter baumannii
10.1111/j.1469-0691.2006.01598.x
Recent articles in CMI have described a novel
subgroup of OXA-type b-lactamases that appears
to be intrinsic in Acinetobacter baumannii [1)3].
These oxacillinases are chromosomally-encoded
and exhibit very poor hydrolytic activities against
carbapenems unless insertion sequence ISAba1 is
located upstream of the blaOXA-51-like gene [3,4].
Approximately 20 variants of the prototype
enzyme, OXA-51, have now been described. We
describe the identiﬁcation of a further novel OXA-
51 variant in A. baumannii that has been designa-
ted OXA-92.
An isolate of A. baumannii was recovered from
the blood culture of a patient hospitalised in a
Greek intensive care unit. MICs of imipenem and
meropenem were determined by the agar dilution
method, and the isolate was screened for blaOXA-51-
like genesusing the external primersOXA-69Aand
OXA-69B [5]. These primers amplify a 975-bp
product that includes the whole coding sequence
of the gene, which allows the different alleles to be
discriminated by sequence analysis. PCR was also
performed using primers speciﬁc for other carbap-
enemase-encoding genes (blaIMP, blaVIM, blaSIM,
blaOXA-23-like, blaOXA-24-like and blaOXA-58) [6,7].
Insertion sequence ISAba1was detected by PCR as
described previously [4], and the genetic element
carrying the blaOXA-51-like gene was investigated
by PCRmapping using ISAba1 forward and blaOXA-
51-like reverse primers.
The imipenem and meropenem MICs for the
isolate were 64 mg ⁄L and 8 mg ⁄L, respectively.
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